0.7787 -0.00 (-0.17%)
After hours: 6:01PM EDT
|Bid||0.7718 x 3100|
|Ask||0.7800 x 800|
|Day's Range||0.7580 - 0.7900|
|52 Week Range||0.3700 - 13.2200|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 15, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||0.91|
Sundial Announces Successful Amendments with Senior Lenders, US$18 Million Convertible Notes Issuance and Close of Bridge Farm Sale
Sundial Announces Results of its Annual General and Special Meeting of Shareholders and Details of the Share Consolidation
This morning, Sundial issued a press release announcing our financial results for the first quarter ended March 31, 2020. Presenting on this morning's call, we have Zach George, chief executive officer; Jim Keough, chief financial officer; and Andrew Stordeur, president and chief operating officer.
CALGARY , May 15, 2020 /CNW/ - Sundial Growers Inc. (Nasdaq: SNDL) ("Sundial" or the "Company") reported its financial and operational results for first quarter 2020 ended March 31, ...
As consideration for the Bridge Farm Disposition, the Purchaser will (i) assume $45 million of debt under Sundial's existing $115 million term debt facility (the "Term Debt Facility"), (ii) assume the contingent consideration liabilities related to the remaining earn-out and additional share obligations under the original Bridge Farm acquisition agreement, dated as of July 2, 2019 , and (iii) cancel approximately 2,700,000 of Sundial common shares currently held by certain members of the Purchaser. Sundial will not receive any cash consideration in connection with the transaction.
As previously announced, the Company received waivers and agreements related to defaults under its existing credit agreements on March 30, 2020 subject to completion of certain defined milestones by April 15, 2020. In addition, the Company is in advanced stages of discussions for the potential sale of its Bridge Farm assets and restructuring of the related credit facility.
LETHBRIDGE, AB , May 5, 2020 /CNW/ - Pathway RX Inc. ("Pathway Rx"), a research company dedicated to developing custom cannabis therapies to treat specific diseases and Swysh Inc. ("Swysh"), a cannabinoid oral health product developer, today announced that they intend to further advance their research to evaluate the potential for medical cannabis to treat COVID-19 and its possible complications. Results from a study by Pathway Rx were recently shared publicly and the research paper was submitted to a scientific journal for peer-review.
With the global economy withering under the COVID-19 pandemic, the odds of a wave of bankruptcies wiping out underperforming cannabis firms are on the rise.
CALGARY , April 24, 2020 /CNW/ - Sundial Growers Inc. (Nasdaq: SNDL) ("Sundial" or the "Company") announces that Mr. Edward (Ted) A. Hellard , former Executive Chairman of Sundial, ...
"We have taken significant actions to restructure our business over the last few months to drive operational efficiencies and adapt to current market conditions," said Zach George, Sundial's Chief Executive Officer. On January 30th, Sundial announced an annualized cost reduction target of $10-15 million.
NEW YORK, NY / ACCESSWIRE / March 31, 2020 / Sundial Growers Inc (NASDAQ:SNDL) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 31, 2020 at 10:30 ...
CALGARY , March 30, 2020 /CNW/ - Sundial Growers Inc. (Nasdaq: SNDL) ("Sundial" or the "Company") reported its financial and operating results for the year ended December 31, 2019 , ...
CALGARY , March 27, 2020 /CNW/ - Sundial Growers Inc. (Nasdaq: SNDL) ("Sundial" or the "Company") announced today that it will reschedule the release of its fourth quarter and fiscal ...
CALGARY , March 12, 2020 /CNW/ - Sundial Growers Inc. (Nasdaq: SNDL) ("Sundial" or the "Company") announced today that it will reschedule the release of its fourth quarter and fiscal ...
Sundial Growers to Announce Fourth Quarter and Fiscal Full-Year 2019 Financial Results on March 12, 2020
CALGARY , Jan. 30, 2020 /CNW/ - Sundial Growers Inc. (Nasdaq: SNDL) ("Sundial" or "the Company") announces certain changes to its executive team and board of directors (the "Board") ...
Canadian licensed cannabis producer Sundial Growers (NASDAQ: SNDL) and Australian importer and manufacturer of medical cannabis Vir Pharma Holdings Pty Ltd. (NASDAQ: VIR) have signed a three-year medical cannabis supply agreement. Under the deal, Sundial will supply medical cannabis oil for Vir Pharma's oral formulation for chronic pain that will be used for sales and clinical studies in Australia. […]The post Sundial to Supply Medical Cannabis Oil for Australian Clinical Studies appeared first on Market Exclusive.
CALGARY and SYDNEY, Jan. 9, 2020 /CNW/ - Sundial Growers Inc. (Nasdaq: SNDL) ("Sundial"), a Canadian licensed cannabis producer and Vir Pharma Holdings Pty Ltd. (Nasdaq: VIR) ("Vir Pharma"), ...
Navigating the process to access medical cannabis can be confusing to patients, and this content rich e-commerce platform aims to streamline the process. In delivering an elevated medical Cannabis experience to Canadians, Sundial will also leverage its research capabilities created by the 50% acquisition of Pathway Rx Inc. (PathwayRx). PathwayRx will implement learnings from its research to develop unique medical cannabis products targeted for use with specific medical conditions.
CALGARY , Dec. 18, 2019 /CNW/ - Sundial Growers Inc. (Nasdaq: SNDL) ("Sundial") and Greg Mills , Chair of the Board, are pleased to announce that Bryan Pinney has been appointed to the Board ...